National Pension Service Purchases 23,411 Shares of IQVIA Holdings Inc. $IQV

National Pension Service boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 375,973 shares of the medical research company’s stock after acquiring an additional 23,411 shares during the period. National Pension Service owned 0.23% of IQVIA worth $72,646,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. California State Teachers Retirement System increased its position in shares of IQVIA by 18,735.4% during the second quarter. California State Teachers Retirement System now owns 49,241,537 shares of the medical research company’s stock worth $9,514,450,000 after purchasing an additional 48,980,106 shares in the last quarter. BlackRock Inc. purchased a new position in IQVIA during the 2nd quarter worth $2,811,292,000. Boston Partners acquired a new position in IQVIA during the 3rd quarter valued at about $676,698,000. Norges Bank acquired a new position in IQVIA during the 4th quarter valued at about $497,445,000. Finally, Victory Capital Management Inc. raised its stake in IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after buying an additional 1,614,063 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent analyst reports. Robert W. Baird upped their price target on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. HSBC reissued a “buy” rating and set a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. Morgan Stanley restated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Finally, Mizuho lifted their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $243.62.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider W. Richard Staub sold 5,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 15,581 shares of company stock valued at $3,796,021. Insiders own 1.70% of the company’s stock.

IQVIA Stock Up 1.9%

IQVIA stock opened at $262.09 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The stock has a market capitalization of $43.14 billion, a PE ratio of 32.52, a price-to-earnings-growth ratio of 2.20 and a beta of 1.18. The business has a 50 day simple moving average of $236.55 and a 200-day simple moving average of $195.92. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $271.80.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.